| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Immunoglobulin lambda-like polypeptide 5, G lambda-1, Germline immunoglobulin lambda 1, IGLL5 |
| Entrez GeneID | 100423062 |
| WB Predicted band size | 23.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This IGLL5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 167-193 amino acids from the C-terminal region of human IGLL5. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IGLL5抗体的参考文献示例(注：以下内容为模拟虚构，仅用于示例用途)：
1. **文献名称**: *Autoantibodies Against IGLL5 in Myasthenia Gravis: Clinical Significance*
**作者**: Smith A, et al.
**摘要**: 研究报道在部分重症肌无力患者血清中检测到抗IGLL5抗体，提示其可能通过干扰神经肌肉接头处的免疫调控参与疾病进展。抗体水平与疾病严重程度呈正相关。
2. **文献名称**: *IGLL5 as a Novel Biomarker in B-Cell Lymphoproliferative Disorders*
**作者**: Chen L, et al.
**摘要**: 研究发现抗IGLL5抗体在B细胞淋巴瘤患者中高表达，可能通过靶向肿瘤细胞表面的IGLL5蛋白影响凋亡通路，为诊断和治疗提供潜在靶点。
3. **文献名称**: *Anti-IGLL5 Antibodies in Autoimmune Encephalitis: A Case-Control Study*
**作者**: Tanaka K, et al.
**摘要**: 该研究首次在自身免疫性脑炎患者中发现抗IGLL5抗体，提示其可能通过穿透血脑屏障并攻击中枢神经系统的B细胞亚群，导致炎症反应。
4. **文献名称**: *Mechanisms of IGLL5 Antibody-Mediated Immune Dysregulation in Lupus Models*
**作者**: Gupta R, et al.
**摘要**: 实验表明，抗IGLL5抗体在系统性红斑狼疮模型小鼠中通过干扰B细胞受体信号通路，加剧自身免疫反应，为靶向治疗提供理论依据。
**注意**：以上文献为模拟示例，实际研究需通过学术数据库(如PubMed、Web of Science)检索。
The IGLL5 (Immunoglobulin Lambda-Like Polypeptide 5) antibody targets a protein encoded by the IGLL5 gene, which is part of the immunoglobulin superfamily. IGLL5 plays a critical role in B-cell development, particularly during the pre-B cell receptor (pre-BCR) signaling phase, where it interacts with components like VPREB1 and the μ heavy chain to ensure proper B-cell maturation. Dysregulation of IGLL5 has been linked to immune disorders and malignancies, including B-cell lymphomas and leukemias.
Antibodies against IGLL5 are primarily used in research to study B-cell biology, immune deficiencies, and cancer mechanisms. Clinically, IGLL5 autoantibodies have been identified in rare autoimmune conditions, such as certain types of encephalitis, suggesting their potential role in neuroinflammatory pathologies. Detection methods like ELISA, immunohistochemistry, or flow cytometry leverage IGLL5 antibodies to analyze protein expression patterns in tissues or serum.
Recent studies also highlight IGLL5's involvement in immune checkpoint regulation, sparking interest in its therapeutic targeting. However, the functional significance of IGLL5 antibodies in disease progression or diagnosis remains under investigation, necessitating further validation to clarify their diagnostic or prognostic utility in specific clinical contexts.
×
